Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TIVICAY 5 MG COMPRIMIDOS DISPERSABLES - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TIVICAY 5 MG COMPRIMIDOS DISPERSABLES

Approved

STANDARD

TIVICAY 5 MG COMPRIMIDOS DISPERSABLES

Viiv Healthcare B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jan 25, 2023
Approval ID: 3fc148787a00a5be
Company: Viiv Healthcare B.V.
Type: Standard

Approval Details

Approval Id: 3fc148787a00a5be
Drug Cima Aemps Name: TIVICAY 5 MG COMPRIMIDOS DISPERSABLES
Register Number: 1130892007
Holder Company Name: Viiv Healthcare B.V.
Marketing Company Name: Laboratorios Viiv Healthcare S.L.
Holder Company Detail Path: /organization/viiv-healthcare-bv
Authorization Date: 2023-01-25
Dosage Form: COMPRIMIDO DISPERSABLE
Dose: 5 MG
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Viiv Healthcare B.V.
Company Detail Path: /organization/viiv-healthcare-bv

Company Information

Pharmaceutical Company Name: ViiV Healthcare BV
Country Name: Netherlands
Website: http://viivhealthcare.com/nl-nl

Active Ingredients

DOLUTEGRAVIR SODIO

5,26 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jan 25, 2023

Approval ID

3fc148787a00a5be

Type

Standard

Back to CIMA-AEMPS Approvals